Skip to main content

Mean Platelet Volume Linked to Mortality in Peritoneal Dialysis Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 22, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Nov. 22, 2023 -- For patients treated with peritoneal dialysis (PD), mean platelet volume (MPV) is associated with all-cause mortality and cardiovascular mortality, according to a study published online Nov. 8 in BMC Cardiovascular Disorders.

Jianghai Wang, from the Dongying People's Hospital in China, and colleagues estimated the relationship between MPV and all-cause and cardiovascular mortality among 1,322 patients treated with PD. The associations were assessed in three models: Model 1 was unadjusted; model 2 was adjusted for age, gender, Charlson comorbidity index, diabetes, hypertension, premorbid cardiovascular diseases, body mass index, and antiplatelet medication; and model 3 had further adjustment for hemoglobin, albumin, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.

A total of 360 deaths were recorded during a median follow-up of 50 months. The researchers found that the risk for all-cause mortality was considerably higher among patients with MPV ≥10.2 fL in all three models (hazard ratios, 0.68, 0.70, and 0.73, respectively). The risk for cardiovascular mortality was also higher among patients with MPV ≥10.2 fL in models 1, 2, and 3 (hazard ratios, 0.63, 0.66, and 0.69, respectively).

"Our findings suggest that high levels of MPV (MPV ≥10.2 fL) is an independent hazards and biological marker for all-cause and cardiovascular mortality in patients treated with PD," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD

WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.